Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

New and potential strategies for the treatment of PMM2-CDG

  • Gámez, Alejandra
  • Serrano, Mercedes
  • Gallego, Diana
  • Vilas, Alicia
  • Pérez, Belén
Background Mutations in the PMM2 gene cause phosphomannomutase 2 deficiency (PMM2; MIM# 212065), which manifests as a congenital disorder of glycosylation (PMM2-CDG). Mutant PMM2 leads to the reduced conversion of Man-6-P to Man-1-P, which results in low concentrations of guanosine 5′-diphospho-D-mannose, a nucleotide-activated sugar essential for the construction of protein oligosaccharide chains. To date the only therapeutic options are preventive and symptomatic. Scope of review This review covers the latest advances in the search for a treatment for PMM2-CDG. Major conclusions Treatments based on increasing Man-1-P levels have been proposed, along with the administration of different mannose derivates, employing enzyme inhibitors or repurposed drugs to increase the synthesis of GDP-Man. A single repurposed drug that might alleviate a severe neurological symptom associated with the disorder is now in clinical use. Proof of concept also exists regarding the use of pharmacological chaperones and/or proteostatic regulators to increase the concentration of hypomorphic PMM2 mutant proteins. General significance The ongoing challenges facing the discovery of drugs to treat this orphan disease are discussed., The authors are grateful to the Spanish families affected by PMM2-CDG who actively participated in this work. Financial support was provided by grant PI19/01155, PI17/00101, B2017/BMD-3721, the Fundación Isabel Gemio/Fundación La Caixa (LCF/PR/PR16/11110018), and the European Regional Development Fund. MS research is supported by the Generalitat de Catalunya (PERIS SLT008/18/00194., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Hepatocyte-like cells differentiated from methylmalonic aciduria cblB type induced pluripotent stem cells: A platform for the evaluation of pharmacochaperoning

  • Briso-Montiano, Álvaro
  • Vilas, Alicia
  • Richard, Eva
  • Ruiz-Sala, Pedro
  • Morato, Esperanza
  • Desviat, Lourdes Ruiz
  • Ugarte, Magdalena
  • Rodríguez-Pombo, Pilar
  • Pérez, Belén
Methylmalonic aciduria cblB type (MMA cblB type, MMAB OMIM #251110), caused by a deficiency in the enzyme ATP:cob(I)alamin adenosyltransferase (ATR, E.C_2. 5.1.17), is a severe metabolic disorder with a poor prognosis despite treatment. We recently described the potential therapeutic use of pharmacological chaperones (PCs) after increasing the residual activity of ATR in patient-derived fibroblasts. The present work reports the successful generation of hepatocyte-like cells (HLCs) differentiated from two healthy and two MMAB induced pluripotent stem cell (iPSC) lines, and the use of this platform for testing the effects of PCs. The MMAB cells produced little ATR, showed reduced residual ATR activity, and had higher concentrations of methylmalonic acid compared to healthy HLCs. Differential proteome analysis revealed the two MMAB HCLs to show reproducible differentiation, but this was not so for the healthy HLCs. Interestingly, PC treatment in combination with vitamin B increased the amount of ATR available, and subsequently ATR activity, in both MMAB HLCs. More importantly, the treatment significantly reduced the methylmalonic acid content of both. In summary, the HLC model would appear to be an excellent candidate for the pharmacological testing of the described PCs, for analyzing the effects of new drugs, and investigating the repurposing of older drugs, before testing in animal models., We wholeheartedly thank the Spanish families affected by MMA who actively participated in this research. This work was funded by the Fundacion Isabel Gemio-Fundación La Caixa [LCF/PR/PR16/11110018], the Instituto de Salud Carlos III (ISCIII),-European Regional Development Fund [PI19/01155] and the Consejería de Educación, Juventud y Deporte, Comunidad de Madrid [B2017/BMD3721].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mitochondrial bioenergetic is impaired in Monocarboxylate transporter 1 deficiency: a new clinical case and review of the literature

  • Stanescu, Sinziana
  • Bravo Alonso, Irene
  • Belanger Quintana, Amaya
  • Pérez, Belén
  • Medina-Díaz, Montserrat
  • Ruiz-Sala, Pedro
  • Paola Flores, Nathaly
  • Buenache, Raquel
  • Arrieta, Francisco
  • Rodríguez Pombo, Pilar
Background: Monocarboxylate transporter 1 (MCT1) deficiency has recently been described as a rare cause of recurrent ketosis, the result of impaired ketone utilization in extrahepatic tissues. To date, only six patients with this condition have been identified, and clinical and biochemical details remain incomplete. Results: The present work reports a patient suffering from severe, recurrent episodes of metabolic acidosis and psychomotor delay, showing a pathogenic loss-of-function variation c.747_750del in homozygosity in SLC16A1 (which codes for MCT1). Persistent ketotic and lactic acidosis was accompanied by an abnormal excretion of organic acids related to redox balance disturbances. Together with an altered bioenergetic profile detected in patient-derived fibroblasts, this suggests possible mitochondrial dysfunction. Brain MRI revealed extensive, diffuse bilateral, symmetric signal alterations for the subcortical white matter and basal ganglia, together with corpus callosum agenesia. Conclusions: These findings suggest that the clinical spectrum of MCT1 deficiency not only involves recurrent atacks of ketoacidosis, but may also cause lactic acidosis and neuromotor delay with a distinctive neuroimaging pattern including agenesis of corpus callosum and other brain signal alterations., This work was funded by grant PI19/01155, B2017/BMD-3721 and the European Regional Development Fund. Open Acces is supported by Fundación Ramón Areces (Grant No. CIVP17A2827).